Brought to you by 
Drug delivery company scPharmaceuticals raises $45.6mm in Series B capital
04 Jan 2017
Executive Summary
scPharmaceuticals Inc. (subcutaneous drug delivery products) raised $45.6mm in its Series B financing round co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. Returning backers 5AM Ventures and Lundbeckfond Venture also participated. ScPharmaceuticals has now raised over $60mm to date through its A and B rounds. The company will use the proceeds for the development of the operational and commercial infrastructure needed to bring Furoscix (diuretic for treatment of heart failure) and sc2Wear Infusor (patch pump device that facilitates subcutaneous drug administration) to market in the US, and toward further development of antibiotic products in its pipeline.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Drug delivery company scPharmaceuticals raises $45.6mm in Series B capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice